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• Circulating myeloid precursors • WBC > 10x10 9 Figure  2 ). 10 The NF1 gene is a tumor suppressor gene encoding for neurofibromin, and is a GTPase activating protein hydrolysing GTP-RAS into GDP-RAS. 10 JMML cells from children with NF1 showed a reduced neurofibromin activity, resulting in elevated GTP-RAS expression. 11 In 2007, Flotho et al. described somatic loss of heterozygosity (LOH) in 4 out of 5 JMML cases with NF1. In the leukemic cells the wild-type NF1 gene was replaced by a second copy of the NF1 mutant 17q arm, resulting from uniparental disomy. 12 In the current issue of this journal, Steinemann et al. 13 describe bi-allelic NF1 gene inactivation in all cases in a larger cohort of JMML patients with NF1. Again, this was either caused by LOH (n=10), or by somatic mutations of the NF1 gene (n=5). This indicates that although NF1 predisposes for JMML and other leukemias, second events are necessary to abolish the complete function of the NF1 gene in the development of malignancies. Recently, comparable bi-allelic mutations in the NF1 gene were also found in non-syndromic AML and T-ALL patients, which underscores the fact that bi-allelic inactivation of the NF1 gene is an important mechanism in hematologic malignancies, but also that it is not JMMLspecific. 14 Germline mutations in the PTPN11 gene have been described in 50% of the Noonan syndrome cases. These mutations differ from the somatic mutations found in JMML. 17 Noonan syndrome is characterized by developmental disorders, short stature, facial dysmorphia, skeletal anomalies and heart defects. Children with Noonan syndrome are at increased risk for developing JMML. However, in Noonan syndrome, JMML seems to behave differently from sporadic JMML as it occurs at a very young age (infancy) and tends to regress spontaneously. [18] [19] [20] Therefore, recognising Noonan syndrome in a JMML patient is important in order to identify those patients who might benefit from a watch and wait policy. 17, 18 Editorials and Perspectives 
RAS gene mutations

c-CBL mutations
Recently Loh et al. identified c-CBL mutations in 17% of the JMML patients, lacking RAS, PTPN11 or NF1 abnormalities (Figure 2 ). c-CBL is an E3 ubiquitin ligase, responsible for the intracellular transport and degradation of a large number of tyrosine kinase receptors, but also has important adaptor functions. One of the proteins regulated by c-CBL is Grb2. This adaptor molecule binds to c-CBL and in this way binding of c-CBL to SOS is prevented. Mutations in c-CBL have been shown to result in a continuous activation of RAS. 21, 22 Other genes of the RAS pathway So up till now, in about 80-85% of the JMML cases a somatic mutation in the RAS pathway is found, indicating that hyperactivation of the RAS pathway plays a central role in the pathogenesis of JMML. Therefore, other genes involved in the RAS-RAF-MEK-ERK pathway have been investigated. Analysis of SHC1, GRB2, GAB1, SOS1, BRAF and MEK 1 and MEK 2 genes revealed no mutations. 23, 24 We and others showed that, upstream, FLT3 mutations are rare and we found no constitutively activated FLT3.
25, 26
JAK-STAT pathway
It has been suggested that JMML is the juvenile counterpart of chronic myelomonocytic leukemia (CMML) which mainly occurs in adults, as also in CMML GM-CSF hypersensitivity is found. However, JAK2 mutations (V617F) which are found in in 3-13% of all CMML cases are a very rare event in JMML, underscoring the differences between JMML and CMML. 26, 27 Using flow cytometry, Kotecha et al. found hyperphosphorylation of pSTAT5 in response to subsaturating concentrations of GM-CSF. This supports the hypothesis that the JAK2-STAT5 pathway plays a collaborating role in the pathogenesis of JMML but that JAK-STAT5 activation mainly seems to occur by upstream of activation of the RAS in the aberrant response of JMML cells to GM-CSF.
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PTEN
Although all above mentioned studies have shown the role of hyperactivation of the RAS pathway in JMML, only few data are available documenting the status of the other components downstream of RAS, like P13K and MAPK. One of the other regulators of the P13K pathway is PTEN, a tumor suppressor gene which antagonizes the function of P13K and subsequently of AKT, and which is involved in cell growth, proliferation, apoptosis and differentiation. Liu et al. found PTEN protein deficiency in 67% of the JMML patients and hypothesized that this deficiency might lead to insufficient negative growth signals to counter the hyperactive RAS pathway. 28 
Epigenetics
It has been suggested that PTEN protein deficiency can be caused by hypermethylation of the promoter region of PTEN. 28 Apart from hypermethylation of PTEN, it was recently shown that other epigenetic changes might play a role in the pathogenesis of JMML as illustrated by Furlan et al. They reported the first JMML patient, also characterized by monosomy 7, treated with a DNA hypomethylating agent. The patient revealed an excellent clinical and molecular-genetic response, as illustrated by the disappearance of the monosomy 7 and hypomethylation of the promoter region of the CALCA gene after treatment. 29 In addition, other JMML studies showed mild hypermethylation of specific genes, like p15, p16 and RASSF1A. 30, 31 These studies are important as they may point towards new, less toxic treatment approaches which are already available for use in the near future for at least subsets of JMML patients.
Treatment and prognosis
To date, the only curative treatment option for JMML is stem cell transplantation (SCT). Intensive chemotherapy does not represent a curative strategy, and splenectomy before transplantation has never been shown to be of benefit. 32 The median survival time without SCT is about one year. 5 In the treatment protocol of the European Working Group on Childhood MDS (EWOG MDS), the 5-year event free survival after transplantation was in the 50% range and the cumulative relapse rate was 35%, with a therapy related mortality rate of 15%. 32 Results of a study performed by the Children's Oncology Group including a farnesyltransferase in the pre-transplantation window are underway. 33 So far, no further data on the effect of treatment with RAS pathway inhibitors are available. As indicated above, hypomethylating agents may be a promising treatment option for the future.
Stem cell transplantation in this relatively young age category of children with JMML harbors the risk of serious toxicity, not only during the procedure but also in later life. Hence, there is a need for unravelling the biology of JMML in order to identify potential drug targets.
Conclusion
JMML is a rare hematologic malignancy in childhood. Increased knowledge of the molecular background has enhanced diagnostic classification, as in more than 80% of the cases mutations in RAS pathway related genes can be found. NF1 is one of the genes which plays an important role in the pathogenesis of JMML. The paper of Steinemann et al. in the current issue 13 of Haematologica underscores the fact that in NF1, for developing JMML, biallelic inactivation is necessary by either mutations or LOH as a second event to abolish the complete function of the NF1 gene.
